Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL.

Breast Cancer Res. 2018 Jun 14;20(1):52. doi: 10.1186/s13058-018-0989-8.

2.

IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.

Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA.

Clin Cancer Res. 2017 Aug 1;23(15):4203-4211. doi: 10.1158/1078-0432.CCR-15-0574. Epub 2017 May 22.

3.

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.

Perez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA.

J Natl Cancer Inst. 2016 Oct 28;109(2). pii: djw207. Print 2017 Feb.

4.
5.

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.

Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA.

Cancer Res. 2016 Jul 1;76(13):3702-10. doi: 10.1158/0008-5472.CAN-15-3091. Epub 2016 Apr 20.

6.

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL.

JAMA Oncol. 2016 Jan;2(1):56-64. doi: 10.1001/jamaoncol.2015.3239.

7.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM.

J Clin Oncol. 2015 Mar 1;33(7):701-8. doi: 10.1200/JCO.2014.57.6298. Epub 2015 Jan 20.

8.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

9.

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.

Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R, Knutson KL, Perez EA.

Cancer Immunol Res. 2014 Oct;2(10):962-9. doi: 10.1158/2326-6066.CIR-14-0059. Epub 2014 Jul 2.

10.

What happens to mental health treatment during pregnancy? Women's experience with prescribing providers.

Weinreb L, Byatt N, Moore Simas TA, Tenner K, Savageau JA.

Psychiatr Q. 2014 Sep;85(3):349-55. doi: 10.1007/s11126-014-9293-7.

11.

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA.

Clin Cancer Res. 2013 Oct 15;19(20):5798-807. doi: 10.1158/1078-0432.CCR-13-0558. Epub 2013 Aug 21.

12.

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.

Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA.

Cancer. 2013 Aug 1;119(15):2675-82. doi: 10.1002/cncr.28130. Epub 2013 Jun 6.

13.

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA.

Breast Cancer Res Treat. 2013 Apr;138(2):427-35. doi: 10.1007/s10549-013-2469-2. Epub 2013 Mar 12.

14.

Seropositivity for influenza A(H1N1)pdm09 virus among frontline health care personnel.

Alagappan K, Silverman RA, Hancock K, Ward MF, Akerman M, Dawood FS, Branch A, De Cicco S, Steward-Clark E, McCullough M, Tenner K, Katz JM.

Emerg Infect Dis. 2013 Jan;19(1):140-3. doi: 10.3201/eid1901.111640.

15.

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B.

J Natl Cancer Inst. 2012 Jan 18;104(2):159-62. doi: 10.1093/jnci/djr490. Epub 2011 Dec 2.

16.

Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.

Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA.

Clin Cancer Res. 2011 Nov 15;17(22):7183-93. doi: 10.1158/1078-0432.CCR-11-0981. Epub 2011 Oct 5.

17.

Importin α7 is essential for zygotic genome activation and early mouse development.

Rother F, Shmidt T, Popova E, Krivokharchenko A, Hügel S, Vilianovich L, Ridders M, Tenner K, Alenina N, Köhler M, Hartmann E, Bader M.

PLoS One. 2011 Mar 29;6(3):e18310. doi: 10.1371/journal.pone.0018310.

18.

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB.

J Clin Oncol. 2010 Oct 1;28(28):4307-15. doi: 10.1200/JCO.2009.26.2154. Epub 2010 Aug 9.

19.

Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E.

Merino VF, Todiras M, Mori MA, Sales VM, Fonseca RG, Saul V, Tenner K, Bader M, Pesquero JB.

J Mol Med (Berl). 2009 Oct;87(10):953-63. doi: 10.1007/s00109-009-0501-0. Epub 2009 Jul 18.

PMID:
19618151
20.

Growth retardation and altered autonomic control in mice lacking brain serotonin.

Alenina N, Kikic D, Todiras M, Mosienko V, Qadri F, Plehm R, Boyé P, Vilianovitch L, Sohr R, Tenner K, Hörtnagl H, Bader M.

Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10332-7. doi: 10.1073/pnas.0810793106. Epub 2009 Jun 11.

21.

The mTPH2 C1473G single nucleotide polymorphism is not responsible for behavioural differences between mouse strains.

Tenner K, Qadri F, Bert B, Voigt JP, Bader M.

Neurosci Lett. 2008 Jan 24;431(1):21-5. Epub 2007 Nov 17.

PMID:
18082956
22.

Normal brain development in importin-alpha5 deficient-mice.

Shmidt T, Hampich F, Ridders M, Schultrich S, Hans VH, Tenner K, Vilianovich L, Qadri F, Alenina N, Hartmann E, Köhler M, Bader M.

Nat Cell Biol. 2007 Dec;9(12):1337-8; author reply 1339. No abstract available.

PMID:
18059353
23.

Influence of human tryptophan hydroxylase 2 N- and C-terminus on enzymatic activity and oligomerization.

Tenner K, Walther D, Bader M.

J Neurochem. 2007 Sep;102(6):1887-1894. doi: 10.1111/j.1471-4159.2007.04664.x. Epub 2007 Jun 1.

24.

Rat corin gene: molecular cloning and reduced expression in experimental heart failure.

Langenickel TH, Pagel I, Buttgereit J, Tenner K, Lindner M, Dietz R, Willenbrock R, Bader M.

Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1516-21. Epub 2004 May 20.

25.

Clinical application of Southern blot hybridization with chemiluminescence detection.

Tenner KS, O'Kane DJ.

Methods Enzymol. 2000;305:450-66. No abstract available.

PMID:
10812619
26.

A laboratorian's perspective on evaluation and implementation of new laboratory tests.

O'Kane DJ, Ebert TA, Hallaway BJ, Roberts SG, Bhuiyan AK, Tenner KS.

Clin Chem. 1997 Sep;43(9):1771-80. Review.

27.
28.

Experimental listeria monocytogenes-lymphadenitis. Pathohistological observations.

Racz P, Kaiserling E, Tenner K, Wuthe HH.

Virchows Arch A Pathol Anat Histol. 1974;363(2):135-48. No abstract available.

PMID:
4212000
29.

Experimental Listeria cystitis. II. Further evidence of the epithelial phase in experimental Listeria infection. An electron microscopic study.

Rácz P, Kaiserling E, Tenner K, Wuthe HH.

Virchows Arch B Cell Pathol. 1973 May 15;13(1):24-37. No abstract available.

PMID:
4350987
30.

[Morphology and pathogenesis of bacillary dysentery in man. Results of three autopsies].

Rácz P, Tenner K, Lennert K, Serény B.

Virchows Arch A Pathol Pathol Anat. 1973 Feb 19;358(4):309-19. German. No abstract available.

PMID:
4632537
31.

[Intranuclear bacteria in experimental listeria monocytogenes infections (author's transl)].

Tenner K, Kaiserling E, Lennert K, Racz P, Wuthe HH.

Virchows Arch B Cell Pathol. 1973;14(1):35-45. German. No abstract available.

PMID:
4355691
32.

Experimental Listeria enteritis. I. An electron microscopic study of the epithelial phase in experimental listeria infection.

Rácz P, Tenner K, Mérö E.

Lab Invest. 1972 Jun;26(6):694-700. No abstract available.

PMID:
4624183
33.

[Intracellular Bacteria in human typhoid fever. Ultrastructure, origin, and function of so-called Rindfleisch cells].

Kaiserling E, Racz P, Tenner K, Lennert K.

Virchows Arch B Cell Pathol. 1972;11(4):343-57. German. No abstract available.

PMID:
4629356
34.

[Morphogenesis of keratoconjunctivitis shigellosa].

Rácz P, Tenner K, Szivessy K.

Orv Hetil. 1971 Oct 17;112(42):2517-20. Hungarian. No abstract available.

PMID:
4943845
35.

[Experimental cystitis listeriosa. I. A lightmicroscope study, with special regard to the facultative intracellular parasitism of Listeria monocytogenes].

Rácz P, Tenner K, Mérö E.

Virchows Arch B Cell Pathol. 1971;8(2):96-105. German. No abstract available.

PMID:
4996733
36.

[Comparative electron microscope study of dysenteric and listerial keratoconjunctivitis].

Tenner K, Ráts P, Sherén B.

Arkh Patol. 1970;32(11):12-6. Russian. No abstract available.

PMID:
4993240
37.

Electron microscopic studies in experimental keratoconjunctivitis listeriosa. I. Penetration of Listeria monocytogenes into corneal epithelial cells.

Rácz P, Tenner K, Szivessy K.

Acta Microbiol Acad Sci Hung. 1970;17(3):221-36. No abstract available.

PMID:
4101180
38.

[Diagnostic problems in thedetection of multiple myeloma in aged patients].

Vas M, Alföldi K, Tenner K, Gara I.

Orv Hetil. 1967 Nov 12;108(46):2188-90. Hungarian. No abstract available.

PMID:
5594949
39.

[Studies on senile emphysema].

Haranghy L, Szemenyei K, Füredi E, Tenner K, Konyár E, Szabó Z.

Acta Med Acad Sci Hung. 1966;22(2):117-24. German. No abstract available.

PMID:
5911019
40.

[ON ORAL MUCO-EPIDERMOID TUMORS].

MARK I, TENNER K, ROZSA I.

Zentralbl Allg Pathol. 1964 Dec 15;106:459-63. German. No abstract available.

PMID:
14324630
41.

[SIGNIFICANCE OF INTRACELLULAR GROWTH OF PATHOGENIC MICROORGANISMS IN KERATOCONJUNCTIVITIS SHIGELLOSA AND LISTERIOSA].

RACZ P, TENNER K.

Verh Dtsch Ges Pathol. 1963;47:403-6. German. No abstract available.

PMID:
14171719

Supplemental Content

Loading ...
Support Center